Table 2 Summarized ratings of indicators retained from the rating round
Title. | Rating criteria and overall assessment (mean, coefficient of variation (%) and selectivity (%)) | ||||||
|---|---|---|---|---|---|---|---|
I-1 | I-2 | I-3 | I-4 | I-5 | I-6 | OVERALL | |
Structure indicators | |||||||
 Availability of multidisciplinary lung cancer team | 4.88 7.01 100.00 | 4.88 7.01100.00 | 4.81 8.38100.00 | 4.88 10.26 93.75 | 4.81 8.38100.00 | 4.56 13.79 93.75 | 4.75 9.42100.00 |
Process indicators | |||||||
 Proportion of clinical stage III NSCLC patients for which a skeletal scintigraphy and a CT or MRI of the brain is done before the initiation of combination therapy | 4.69 10.21 100.00 | 4.56 11.23100.00 | 4.44 14.18 93.75 | 4.50 18.14 93.75 | 4.44 14.18 93.75 | 4.56 13.79 93.75 | 4.50 14.05 93.75 |
 Proportion of NSCLC patients in advanced stages who receive performance status assessment | 4.81 11.30 93.75 | 4.50 19.88 87.50 | 4.62 15.54 87.50 | 4.38 21.88 81.25 | 4.69 12.84 93.75 | 4.44 16.39 87.50 | 4.50 16.23 87.50 |
 Proportion of NSCLC patients who receive EGFR test before combination therapy | 4.81 8.38100.00 | 4.62 13.39 93.75 | 4.56 11.23100.00 | 4.62 10.81100.00 | 4.06 26.16 75.00 | 4.38 24.86 87.50 | 4.56 13.79 93.75 |
 Proportion of pathology report available in the chart for NSCLC patients who have surgical resection | 4.81 11.30 93.75 | 4.81 8.38100.00 | 4.75 12.15 93.75 | 4.56 17.84 81.25 | 4.50 19.88 87.50 | 4.69 12.84 93.75 | 4.75 14.38 87.50 |
 Proportion of NSCLC patients who obtain FEV1 and DLCO within 2 weeks before lung resection | 4.75 9.42 100.00 | 4.62 13.39 93.75 | 4.69 10.21100.00 | 4.56 13.79 93.75 | 4.56 13.79 93.75 | 4.69 12.84 93.75 | 4.62 10.81100.00 |
 Proportion of NSCLC patients who receive ECG within 2 weeks before lung resection | 4.56 13.79 93.75 | 4.56 13.79 93.75 | 4.62 10.81100.00 | 4.44 16.39 87.50 | 4.44 20.10 87.50 | 4.56 15.94 87.50 | 4.50 16.23 87.50 |
 Proportion of NSCLC patients staging I or II without contraindications who undergo curative resection | 4.75 12.15 93.75 | 4.69 10.21100.00 | 4.75 12.15 93.75 | 4.75 9.42100.00 | 4.62 15.54 87.50 | 4.50 19.88 87.50 | 4.69 12.84 93.75 |
 Proportion of NSCLC patients staging IA without contraindications who receive lobectomy | 4.56 15.94 87.50 | 4.50 14.05 93.75 | 4.88 7.01100.00 | 4.69 10.21100.00 | 4.19 21.74 81.25 | 4.50 14.05 93.75 | 4.50 14.05 93.75 |
 Proportion of NSCLC patients staging IB to II who receive lobectomy with adjuvant chemotherapy or lobectomy only | 4.44 21.72 81.25 | 4.50 11.48100.00 | 4.56 11.23100.00 | 4.50 14.05 93.75 | 4.38 21.88 81.25 | 4.50 16.23 87.50 | 4.50 14.05 93.75 |
 Proportion of NSCLC patients with stage IIA, IIB or ΙΙΙA who receive adjuvant chemotherapy after curative resection | 4.62 13.39 93.75 | 4.56 13.79 93.75 | 4.56 11.23100.00 | 4.62 10.81100.00 | 4.38 18.43 81.25 | 4.56 13.79 93.75 | 4.44 14.18 93.75 |
 Proportion of NSCLC patients with stage IIA, IIB or ΙΙΙA who receive cisplatin-based adjuvant chemotherapy within 3 to 4 weeks after undergoing curative resection | 4.69 10.21 100.00 | 4.56 11.23100.00 | 4.50 14.05 93.75 | 4.44 14.18 93.75 | 4.31 18.39 81.25 | 4.75 9.42100.00 | 4.62 10.81100.00 |
 Proportion of NSCLC patients staging ΙΙΙB with malignant effusion or Ις who receive first-line chemotherapy | 4.88 7.01 100.00 | 4.81 11.30 93.75 | 4.75 9.42100.00 | 4.81 8.38100.00 | 4.56 15.94 87.50 | 4.81 8.38100.00 | 4.75 9.42100.00 |
 Proportion of NSCLC patients staging ΙΙΙB or Ις who receive imaging study to assess response of chemotherapy at least once before the completion of four cycles | 4.88 7.01 100.00 | 4.75 9.42100.00 | 4.81 8.38100.00 | 4.75 9.42100.00 | 4.50 18.14 81.25 | 4.56 17.84 93.75 | 4.81 8.38100.00 |
 Proportion of NSCLC patients staging I or II pathologically who receive postoperative radiation therapy after incomplete surgical resection | 4.69 12.84 93.75 | 4.62 13.39 93.75 | 4.56 13.79 93.75 | 4.56 13.79 93.75 | 4.50 16.23 87.50 | 4.69 12.84 93.75 | 4.56 13.79 93.75 |
 Proportion of locally advanced NSCLC patients who receive neo-adjuvant chemotherapy | 4.50 16.23 87.50 | 4.56 13.79 93.75 | 4.50 14.05 93.75 | 4.56 11.23100.00 | 4.38 18.43 81.25 | 4.56 15.94 87.50 | 4.44 16.39 87.50 |
 Proportion of locally advanced NSCLC patients with performance status 0 or 1 who receive combination therapy | 4.88 7.01 100.00 | 4.88 7.01100.00 | 4.81 8.38100.00 | 4.75 12.15 93.75 | 4.75 12.15 93.75 | 4.56 13.79 93.75 | 4.88 7.01100.00 |
Communication indicators | |||||||
 Proportion of NSCLC patients who are informed of a follow-up plan at the time of discharge from hospital | 4.88 10.26 93.75 | 4.88 7.01100.00 | 4.94 5.06100.00 | 4.88 7.01100.00 | 4.88 7.01100.00 | 4.69 15.02 87.50 | 4.88 10.26 93.75 |
 Proportions of active smokers with NSCLC who have had smoking cessation counseling documented | 4.75 21.05 93.75 | 4.44 24.64 87.50 | 4.56 22.59 93.75 | 4.62 13.39 93.75 | 4.38 21.88 81.25 | 4.50 16.23 87.50 | 4.56 17.84 93.75 |
 Proportion of NSCLC patients staging IA who are recommend adjuvant chemotherapy after curative resection (lower score: better) | 4.69 12.84 93.75 | 4.56 15.94 87.50 | 4.62 13.39 93.75 | 4.44 16.39 87.50 | 4.38 18.43 81.25 | 4.44 20.10 87.50 | 4.50 16.23 87.50 |
Outcome indicators | |||||||
 Post-operative complications | 4.00 28.87 68.75 | 4.31 18.39 81.25 | 4.38 18.43 81.25 | 4.12 23.21 75.00 | 4.00 27.39 68.75 | 4.31 20.25 75.00 | 4.00 24.15 68.75 |